既往接受艾曲泊帕或罗米司亭治疗后换用阿伐曲泊帕的免疫性血小板减少症成人患者:美国多中心研究
该研究为美国四家三级免疫性血小板减少症(ITP)转诊中心的回顾性观察研究,纳入44例既往接受艾曲泊帕或罗米司亭治疗后换用阿伐曲泊帕的成人ITP患者,平均ITP病程8.3年,中位既往ITP治疗数为4种。换用阿伐曲泊帕后,41/44例(93%)达血小板反应(≥50×10⁹/L),38/44例(86%)达完全反应(≥100×10⁹/L);全部患者中位血小板计数在艾曲泊帕或罗米司亭治疗时为45×10⁹/L,阿伐曲泊帕治疗时为114×10⁹/L(p<0.0001)。
要点
- 换用阿伐曲泊帕后93%(41/44)达血小板反应(≥50×10⁹/L),86%(38/44)达完全反应(≥100×10⁹/L)。
- 全部患者中位血小板计数:艾曲泊帕或罗米司亭45×10⁹/L vs 阿伐曲泊帕114×10⁹/L(p<0.0001)。
- 因罗米司亭/艾曲泊帕无效而换药者中位血小板计数:原药28×10⁹/L vs 阿伐曲泊帕88×10⁹/L(p=0.025)。
核心结论
- 在既往接受过大量治疗的慢性ITP人群中,阿伐曲泊帕在罗米司亭或艾曲泊帕治疗后有效,即使对既往TPO-RA反应不足的患者也有高反应率。
研究设计与样本
- 回顾性观察研究,纳入美国四家三级ITP转诊中心既往接受艾曲泊帕或罗米司亭治疗后换用阿伐曲泊帕的成人ITP患者44例。
- 患者平均ITP病程8.3年,既往ITP治疗中位数为4种(范围未报告)。
主要发现
- 阿伐曲泊帕治疗时41/44例(93%)达血小板反应(≥50×10⁹/L),38/44例(86%)达完全反应(≥100×10⁹/L)。
- 全部患者中位血小板计数在艾曲泊帕或罗米司亭治疗时为45×10⁹/L,阿伐曲泊帕治疗时为114×10⁹/L(p<0.0001)。
- 因罗米司亭/艾曲泊帕无效而换药的患者中,中位血小板计数在原药治疗时为28×10⁹/L,阿伐曲泊帕治疗时为88×10⁹/L(p=0.025)。
- 换药前接受伴随ITP药物治疗的患者中57%在换药后停用伴随药物,其中接受长期皮质类固醇治疗者63%停用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO-RA) but not another. Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral TPO-RA. We performed a retrospective observational study of adults with ITP who switched from eltrombopag or romiplostim to avatrombopag at four US tertiary ITP referral centres. Forty-four patients were included, with a mean ITP duration of 8.3 years and a median (range) of four prior ITP treatments. On avatrombopag, 41/44 patients (93%) achieved a platelet response (≥50 × 109 /l) and 38/44 patients (86%) achieved a complete response (≥100 × 109 /l). In all patients, the median platelet count on eltrombopag or romiplostim was 45 × 109 /l vs 114 × 109 /l on avatrombopag (p < 0.0001); in patients switched for ineffectiveness of romiplostim/eltrombopag, it was 28 × 109 /l on romiplostim/eltrombopag vs 88 × 109 /l on avatrombopag (p = 0.025). Fifty-seven percent of patients receiving concomitant ITP medications before switching discontinued them after switching, including 63% of patients receiving chronic corticosteroids. In a heavily pretreated chronic ITP population, avatrombopag was effective following therapy with romiplostim or eltrombopag, with high response rates even in patients with inadequate response to a prior TPO-RA.
引用
- Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022. PMID: 35179784. doi:10.1111/bjh.18081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。